A phase 2, multicenter, randomized, open-label study of a continuous hepatic arterial infusion combination therapy with OPC-18 and 5-FU versus the best salvage therapy (BST) in patients with highly advanced hepatocellular carcinoma
Phase 2
- Conditions
- Advanced hepatocellular carcinoma
- Registration Number
- JPRN-jRCT2080220441
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with highly advanced hepatocellular carcinoma for which resection therapy or local therapy is inapplicable due to advanced vascular invasion, patients with no remote metastasis (extrahepatic metastasis), patients who have not received intra-arterial hepatic chemoembolization or systemic chemotherapy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy/safety
- Secondary Outcome Measures
Name Time Method